1037834-62-0

Basic information

• Product Name: 6-Azaspiro[2.5]octane hydrochloride
• Synonyms: 6-Azaspiro[2.5]octane hydrochloride
• CAS NO: 1037834-62-0
• Molecular Formula: C₇H₁₃N*ClH
• Molecular Weight: 147.64576
• Mol File: 1037834-62-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Azaspiro[2.5]octane hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Azaspiro[2.5]octane hydrochloride(1037834-62-0)
• EPA Substance Registry System: 6-Azaspiro[2.5]octane hydrochloride(1037834-62-0)

Safety Data

• Hazardous Substances Data: 1037834-62-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Azaspiro[2.5]octane hydrochloride is used as a precursor in the synthesis of various drugs, particularly those targeted at neurological disorders and mental health conditions. Its structural features make it a valuable component in the development of new therapeutic agents.
Used in Metal-Organic Frameworks:
6-Azaspiro[2.5]octane hydrochloride is used as a ligand in metal-organic frameworks. Its incorporation into these structures can enhance their properties, such as stability, porosity, and catalytic activity, making them suitable for applications in gas storage, separation, and catalysis.
Used in Organic Synthesis:
6-Azaspiro[2.5]octane hydrochloride is used as a catalyst in organic synthesis. Its ability to facilitate certain chemical reactions can improve the efficiency and selectivity of synthetic processes, leading to the production of desired compounds with fewer side reactions.
Used in Asymmetric Synthesis:
6-Azaspiro[2.5]octane hydrochloride is used as a chiral building block in asymmetric synthesis. Its unique structure and properties can be exploited to create enantiomerically pure compounds, which are essential in the pharmaceutical industry for the development of drugs with specific biological activities.
Used in Chemical Research and Development:
6-Azaspiro[2.5]octane hydrochloride is used as a valuable resource in chemical and pharmaceutical research and development. Its exploration in various applications can lead to the discovery of new compounds and materials with potential uses in different industries.

Upstream product

• 138163-12-9 benzyl 4-methylene-1-piperidinecarboxylate 
• 20778-47-6 (1-cyanomethyl-cyclopropyl)-acetonitrile 
• 1037834-61-9 N-cbz-6-azaspiro[2.5]octane 

Relevant articles and documents

PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF

Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.

Straightforward access to cyclic amines by dinitriles reduction

1,1,3,3-Tetramethyldisiloxane (TMDS) and polymethylhydrosiloxane (PMHS), when associated with titanium(IV) isopropoxide, provide two convenient systems for the reduction of nitriles into the corresponding primary amines. Kinetics of the two systems have been studied by 1H NMR and demonstrated that reduction with PMHS occurs faster than with TMDS. These two titanium-based systems reduce both aromatic and aliphatic nitriles in the presence of Br, CC, NO2, OH, and cyclopropyl-ring. In the case of cyclopropyl-nitriles, the formation of secondary amines, which come from an intermolecular reductive alkylation reaction was observed. This result was exploited for the reduction of dinitriles, which led, in one-step, to azepane, piperidine, pyrrolidine, and azetidine derivatives through an intramolecular reductive alkylation reaction.

INHIBITORS OF SERINE PALMITOYLTRANSFERASE

This invention provides compounds of the formula (I) useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial infarction, hypertension, congestive heart failure, cardiomyopathy, atherosclerosis, dyslipidemia, sepsis, liver damage, retinal degenerative disorders, cachexia, emphysema, hepatitis C infections, HIV infections and inflammatory disorders and useful in methods for raising HDL plasma levels in a mammal. The compounds of this invention can also be used to prevent damage or loss of pancreatic islet beta cells (such as in the case of pancreatic beta cell apoptosis, including those related to insulin-dependent diabetes mellitus).